Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levoketoconazole open-label extension for endogenous Cushing's syndrome
NL-OMON49258Phase 3Completed
- Sponsor
- Strongbridge Biopharma
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of levoketoconazole in Cushing's syndrome, sponsored by Strongbridge Biopharma. Primary endpoints: Long-term safety, Proportion of subjects by mean urinary free cortisol category and 6 more. Started Feb 2020; status: completed.
02
Drugs
levoketoconazole
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NL-OMON49258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49258.